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10.Delirium is a severe and common complication following transcatheter aortic valve
implantation (TAVI). We sought to identify the prevalence and risk factors associated
with the development of postprocedural delirium in patients aged over 60 years who
underwent elective TAVI for aortic stenosis. Overall, 1,051 articles were searched, from
which 9 studies were included. The prevalence of delirium following TAVI was higher in
studies that assessed delirium for a minimum of 3 consecutive days (24.9%) compared
with the studies that did not (2%). There were large effect sizes (d > 0.8) for 3 risk factors:
acute kidney injury (odds ratio [OR] 5, p< 0.001), transapical approach (OR 4, p< 0.001)
and carotid artery disease (OR 4, p < 0.001), whilst small effect sizes were found for a his-
tory of atrial fibrillation, prior stroke/transient ischemic attack, peripheral artery disease,
hypertension, and prior cognitive impairment. In conclusion, 23% of patients 60 years
and over who underwent TAVI experience delirium, a preventative cause of cognitive
impairment and dementia. Recognition of risk factors for delirium after TAVI, such as a
history of carotid artery disease, development of acute kidney injury, or use of a transapi-
cal approach, provides an opportunity to implement proven delirium preventative meas-
ures. © 2018 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY license. (http://creativecommons.org/licenses/by/4.0/) (Am J Cardiol
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1016/j.amjcard.2018.08.037Delirium (a deficit of attention with an acute and fluctu-
ating course)1 is a common complication following trans-
catheter aortic valve implantation (TAVI). Patients with
delirium following TAVI have twice the length of hospital
stay,2 nearly 3 times the risk of increased hospital readmis-
sions and mortality within 180 days of the procedure,3 and
are twice as likely to be admitted to a rehabilitation facil-
ity,2 compared with their nondelirious counterparts. In the
general population aged over 85 years, delirium has been
associated with increased risk of incident dementia (odds
ratio [OR] 9, 95% confidence interval [CI] 2.1 to 35.1)
and cognitive decline (OR 3, 95% CI 1.4 to 5.5).4 In older
hospitalized adults, there is evidence that delirium is pre-
ventable in 20% to 30% of cases.5,6 A study using multi-
component interventions (orientation protocol, cognitively
stimulating activities, early mobilization, andnonpharmacologic sleep, vision, hearing, and dehydration
protocols), found the incidence of delirium was signifi-
cantly lower in the intervention group than the usual-care
group (10% vs 15%, p = 0.02).6 It is therefore important to
identify those at high-risk of developing postprocedural
delirium following TAVI in order to target potentially pre-
ventative measures. This systematic review set out to exam-
ine the period prevalence and risk factors for delirium in
TAVI patients.Methods
The primary outcome of interest was the period preva-
lence of delirium identified using a standardized method
such as the Confusion Assessment Method (CAM)7 or the
Diagnostic and Statistical Manual of Mental Disorders-IV
(DSM-IV).8 Studies published in English from the time of
the first TAVI procedure in 2002 until 12 February 2017
were included. Studies were excluded where there were
mixed sample studies (e.g. TAVI and surgical aortic valve
replacement) and the results for different operative types
were not presented independently. Key search terms and
databases searched have been included in the Supplement.
Two independent reviewers (ET and SH) screened studies
at title/abstract level and at full text level, assessed the qual-
ity of the evidence using the Joanna Briggs Institute (JBI)
Critical Appraisal Checklist for Studies Reporting Preva-
lence Data9 (Supplement Table 1), and extracted data using
a predefined data extraction template. Any disagreements
were resolved through discussion.
Table 1
Summary of the included studies. CAM= Confusion Assessment Method; DSM-IV =Diagnostic and Statistical Manual of Mental Disorders-IV; P = prospec-
tive; PO = postoperatively; R = retrospective




Delirium assessment Timing of
delirium
assessment
Abawi (2016) Netherlands R 268 80 (7) 36 (13%) DSM-IV Hospital stay.
Assmann (2016) Netherlands P 89 80 (6) 25 (28%) DSM-IV Hospital stay.
Eide Norway P 63 85 (3) 28 (44%) CAM 1 to 5 days PO.
Erdoes (2012) Switzerland P 44 78 (6) 0 (0%) CAM Prior to, and
at 1-, 4-, 5- and 6-
days PO.




Huded (2016) USA R 294 83 (8) 61 (21%) CAM, CAM-ICU and DSM-IV Hospital stay.
Maniar (2016) USA R 168 81 (8) 49 (29%) CAM-ICU Hospital stay.
Sharma (2016) Canada P 210 84 (6) 45 (21%) CAM and CAM-ICU 1 to 3 days PO.
Tse (2015) Canada R 117 81 (8) 32 (27%) DSM-IV Hospital stay.
ARTICLE IN PRESS
2 The American Journal of Cardiology (www.ajconline.org)Meta-analyses were carried out using the Comprehen-
sive Meta-Analysis Software (Version 3.3.070, Biostat,
Englewood, NJ). Random-effects modeling was used as
there was insufficient overlap in study methodology and
statistical heterogeneity was high (estimated using chi-
squared). Effect sizes were calculated by converting OR to
Cohen’s d and were classified as either large (d > 0.8),
medium (d > 0.5) or small (d > 0.2).Results
A total of 1,309 titles were screened in this review
(Figure 1). Following the removal of duplicate articles, 81
articles were retrieved for full text detailed examination. In
total, 9 studies were included in the final review and meta-
analyses (see Table 1 for an overview of the included stud-
ies). No studies were excluded on the basis of methodologi-
cal quality (Supplement Table 1). All 9 studies used an
appropriate sample frame, described the study subjects and
setting in detail and used valid methods for the identifica-
tion of delirium. The study by Maniar et al. (2016)10 scored
the highest (7 of 9) on the JBI Critical Appraisal Checklist
for Studies Reporting Prevalence Data.9 It was the only
study to report confidence intervals on the prevalence of
delirium. None of the included studies were adequately
powered to identify the prevalence of delirium (See Supple-
ment Table 1 for calculations). The largest sample size
(n = 294) was in the study by Huded et al.2
The results from the meta-analyses on the prevalence of
delirium following TAVI are presented in Figure 2. The
pooled prevalence of delirium following TAVI was 23%
(95% CI 16.9 to 29.7). The pooled prevalence of delirium
of studies that assessed for delirium at least once a day for a
minimum of 3 days following the TAVI procedure was
24.9% (95% CI 19.1 to 31.6); whereas the pooled preva-
lence of studies11,12 that did not assess for delirium daily
for all 3 days following the TAVI procedure was 2% (95%
CI 0.4 to 8.9). The prevalence of delirium following TAVIusing the CAM7 or CAM-ICU13 was 23% (95% CI 15.4 to
33.2), and using the DSM-IV8 was 21% (95% CI 15.4 to
28.5).
Risk factors for the development of delirium post TAVI
were assessed in 7 studies.2,10,14−18 Meta-analyses on pre-
and periprocedural variables for the development of delir-
ium are presented in Table 2 and Supplement Table 2. The
meta-analyses contain a mix of mainly univariate
OR data and multivariate OR data (from the study by
Sharma et al.15). Pooling of post-TAVI risk factors (i.e. the
development of cardiac tamponade, atrial fibrillation, infec-
tion, and hospital length of stay) for the development of
delirium following TAVI was not possible as only one
study reported on each postprocedural variable.
Independent analyses identified that the prevalence of
delirium was significantly associated with 6 preprocedural
risk factors. The presence (vs the absence) of carotid artery
disease (OR 4, 95% CI 2.2 to 8.7, p <0.001) had the largest
impact on delirium (d = 0.81); while the presence of atrial
fibrillation, cognitive impairment, hypertension, peripheral
artery disease, and prior stroke/TIA displayed a smaller
association with delirium (d < 0.2).
Increased age, body mass index, European system for
cardiac operative risk evaluation, left ventricular ejection
fraction, aortic valve area, glomerular filtration rate, male
sex, chronic obstructive pulmonary disease, coronary artery
disease, prior coronary artery bypass grafting, diabetes,
hemoglobin, New York Heart Association Class of Heart
Failure III-IV or American Society of Anesthesiologists
Physical Status Class 4 were not significantly associated
with increased risk of developing delirium following
TAVI.
There were 2 periprocedural risk factors that were signif-
icantly associated with delirium following TAVI: acute kid-
ney injury (OR 5, 95% CI 2.2 to 9.7, p < 0.001) and
transapical approach (OR 4, 95% CI 2.3 to 9.0, p < 0.001).
Both risk factors had a large impact on the presence of
delirium (d = 0.85 and d = 0.83 respectively).
Figure 1. PRISMA search protocol. TAVI = transcatheter aortic valve implantation.
ARTICLE IN PRESS
VALVULAR HEART DISEASE 3Discussion
This systematic review found that nearly 1-in-4 older
adults developed delirium post TAVI. A range of risk fac-
tors for the development of delirium post TAVI were iden-
tified; acute kidney injury (5 times the risk), transapical
approach (4 times the risk), a history of carotid artery dis-
ease (4 times the risk), and 2 times the risk for the following
factors: prior cognitive impairment, atrial fibrillation, prior
stroke/TIA, peripheral artery disease, and hypertension.
Taken together, these findings have highlighted that delir-
ium affects a large proportion of older adults, and that a
range of risk factors may be important for clinical planning
and management of this severe medical complication.The time-frame for the assessment of delirium post
TAVI was found to be important. Two studies identified
that delirium prevalence peaks at 2 days post TAVI.16,17
The prevalence of delirium following TAVI was higher in
studies that assessed delirium for a minimum of 3 consecu-
tive days (25%) compared with the studies that did not
(2%).11,12
The prevalence of delirium in TAVI patients is higher in
reported figures in otolaryngological (12%) and general
surgery cohorts (13%), and less than in cardiac surgeries
(up to 51%).19 This may be due to inherently different
patient profiles at baseline and differences associated with a
minimally invasive procedure compared with cardiac sur-
gery requiring sternotomy. Increased age and multiple
Figure 2. Forest plots; (A) Overall pooled prevalence, (B) Pooled prevalence for studies where delirium was assessed for 3-days postoperatively and (C)
Pooled prevalence for studies where delirium was assessed for 3-days postoperatively. df = degrees or freedom.
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delirium across a range of hospital settings.5 TAVI patients
are typically older and have multiple comorbidities com-
pared with patients who underwent surgical aortic valve
replacement.20 In addition, risk factors for aortic steno-
sis21,22 overlap with risk factors for dementia (including
hypertension,23 diabetes,23 and obesity23), which in turn are
associated with increased risk for delirium.24 How the rates
of delirium following TAVI, a minimally invasive proce-
dure, compared with surgical aortic valve replacement is
beyond the scope of this review, but one study suggests the
prevalence of delirium following surgical aortic valve
replacement may be as high as 66%.14
The identification of risk factors is critical, as it enables
for known delirium intervention strategies6 to be imple-
mented in those who will benefit most. The transapical
approach (a more invasive procedure where the aortic valveis accessed directly through the left ventricular apex rather
than the femoral artery)25 carried 4 times the delirium risk
as compared with the transfemoral approach in our study.
The underlying mechanism behind the difference in delir-
ium risk is unclear, largely because no studies examining
delirium as an outcome have randomized participants
between the two types of access. There may be a tendency
for patients believed to be at increased risk of cerebral
emboli to be selected for the transapical approach rather
than transfemoral approach despite inconclusive evidence
that the transapical approach reduces the rate of new cere-
bral emboli.26 Patients selected for the transapical approach
also tend to have higher rates of peripheral arterial disease,
coronary artery disease, and carotid stenosis than their
counterparts selected for the transfemoral approach.27 More
research is required to establish if the transapical approach
is a modifiable risk factor for the development of delirium,
Table 2
Meta-analyses on pre- and periprocedural variables for the development of delirium following TAVI
Variable Studies N OR or *SDM (95% CI) p value Cohen’s d Heterogeneity Chi2
Age Abawi, Eide, Huded and Maniar. 793 0.10* (¡0.07-0.27) 0.261 0.04 2.73, df = 3, p = 0.435.
ASA Eide and Maniar. 231 0.78 (0.31-1.95) 0.595 ¡0.14 0.00, df = 1,p = 0.951
AF Abawi, Huded, Maniar and Sharma. 940 1.9*2 (1.37-2.69) <0.001 0.36 0.39, df = 3, p = 0.943
AVA Eide and Huded. 357 ¡0.09* (¡0.34-0.15) 0.466 0.04 0.17, df = 1, p = 0.679
BMI Abawi and Maniar. 436 ¡0.09* (¡0.33-0.15) 0.456 0.04 0.50, df = 1, p = 0.480
Carotid artery disease Abawi and Sharma. 478 4.34 (2.17-8.68) <0.001 0.81 0.42, df = 1, p = 0.519
CI Huded and Tse. 411 2.29 (1.08-4.88) 0.031 0.46 0.63, df = 1, p = 0.429
COPD Abawi, Assmann, Huded, Maniar and Sharma. 1029 1.08 (0.75-1.56) 0.688 0.04 2.51, df = 4, p = 0.643
CAD Abawi, Huded, Maniar and Tse. 847 1.39 (0.86-2.24) 0.183 0.18 3.14, df = 3, p = 0.370
Diabetes Abawi, Assmann, Huded and Maniar. 819 1.02 (0.71-1.46) 0.910 0.01 0.37, df = 3, p = 0.947
EuroSCORE Abawi and Eide. 331 0.24 (¡0.05-0.52) 0.108 0.09 0.79, df = 1, p = 0.373
GFR Abawi and Maniar. 436 ¡0.07 (¡0.57-0.43) 0.791 0.01 4.28, df = 1, p = 0.039
Hemoglobin Huded and Maniar. 462 ¡0.08 (¡0.30-0.13) 0.448 0.04 0.81, df = 1, p = 0.369
Hypertension Abawi, Huded, Maniar and Tse. 847 1.75 (1.08-2.84) 0.024 0.31 2.93, df = 3, p = 0.403
LVEF Eide and Huded. 357 ¡0.01 (-0.25-0.24) 0.955 0.00 0.01, df = 1, p = 0.921
Men Abawi, Assmann, Eide, Huded and Maniar. 882 1.15 (0.83-1.59) 0.398 0.08 3.01, df = 4, p = 0.555
NYHA III-IV Abawi, Assmann, Eide and Maniar. 588 1.15 (0.70-1.89) 0.574 0.08 2.27, df = 3, p = 0.518
Peripheral artery disease Abawi, Huded, Maniar, Sharma and Tse. 1057 1.87 (1.02-3.41) 0.043 0.34 12.22, df = 4, p = 0.016
Prior CABG Abawi and Huded. 562 0.84 (0.51-1.38) 0.481 ¡0.01 0.02, df = 1, p = 0.901
Stroke/TIA Abawi, Huded, Sharma and Tse. 889 1.94 (1.25-3.04) 0.004 0.37 1.70, df = 3, p = 0.636
Acute Kidney Injury Huded and Maniar. 462 4.67 (2.24-9.74) <0.001 0.85 0.01, df = 1, p = 0.910
Transapical approach Abawi, Huded, Maniar and Tse. 1057 4.49 (2.2‘5-8.98) <0.001 0.83 16.00, df = 4, p = 0.003
ASA=American Society of Anesthesiologists Physical Status Class 4; AF = atrial fibrillation; AVA= aortic valve area; BMI = body mass index; CABG= coro-
nary artery bypass grafting; CAD= coronary artery disease; CI = cognitive impairment; COPD= chronic obstructive pulmonary disease; EuroSCORE=European
system for cardiac operative risk evaluation; GFR = glomerular filtration rate; LVEF = left ventricular ejection fraction; NYHA III-IV =New York Heart Associa-
tion Class of Heart Failure III-IV; OR = odds ration; SDM= standard difference of means, and TIA = transient ischemic attack.
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ing mechanism of delirium TAVI patients. Although the
evidence is not specific to TAVI, an association between
microemboli, new strokes and postoperative neurocognitive
decline has not been identified in patients who underwent
cardiovascular interventions.28 An emerging theory attrib-
utes postoperative delirium and cognitive decline to under-
lying cerebrovascular disease in cardiovascular surgery
patients.28
A potentially modifiable risk factor for the development
of delirium in patients who underwent TAVI is acute kid-
ney injury (over 5 times the risk, as compared with no kid-
ney injury). While there is no standard protocol for the
prevention of acute kidney injury during TAVI, a recent
review has identified that adequate hydration and the avoid-
ance of nephrotoxic medications remain the mainstay of
preventative therapy.29 However, overhydration must also
be avoided as it may lead to congestive heart failure.29
Therefore, further research is required.
Carotid artery disease was the only preprocedural risk fac-
tor for delirium following TAVI to have a large effect size
(4 times the risk, as compared with no carotid artery disease)
in the present study. Pooled figures also identified that a his-
tory of hypertension was significantly associated with the
development of delirium in patients who underwent TAVI
procedure. Both carotid artery disease and hypertension are
known risk factors for delirium in patients who underwent
cardiac surgery.30 TAVI patients with a history of prior cog-
nitive impairment were also at increased risk of developing
of delirium following their procedure (2 times the risk). Priorcognitive impairment is an established risk factor for the
development of delirium across several hospital settings.19
The homogeneity of the age of TAVI patients may help
to explain why increased age was not found to be a prepro-
cedural risk factor for the development of delirium within
this population. While male sex, American Society of
Anesthesiologists classification > 3 and New York Heart
Association Class of Heart Failure III-IV were not found to
be risk factors for the development of delirium in this
review of TAVI patients, they have been found to be risk
factors for delirium in other hospital settings.19
The limitations of this systematic review are firstly that
the review only included studies published in English. Sec-
ondly, due to the scarcity of literature, the review included
all 9 studies reporting on the prevalence of delirium, despite
no studies being adequately powered to detect prevalence
of delirium in TAVI patients. Overall, the methodological
quality of the studies assessed using the JBI Critical
Appraisal Checklist for Studies Reporting Prevalence Data9
was relatively mediocre. The mean score was 5 of 9. How-
ever it is acknowledged that the prevalence of delirium was
not the primary focus of the 9 cohort studies.
This systematic review has implications for clinical prac-
tice for patients who underwent TAVI and have been summa-
rized in Figure 3. Proven delirium preventative measures,6
should be considered as part of postprocedural care for
patients who undergo transapical approach TAVI, with a his-
tory of carotid artery disease, cognitive impairment, atrial
fibrillation, stroke/TIA, peripheral artery disease, and hyper-
tension. Where possible, acute kidney injury should be
Figure 3. Clinical application of risk factors for postprocedural delirium in
TAVI patients to consider. AF = atrial fibrillation; CI = cognitive
impairment; HT = hypertension; PAD = peripheral artery disease;
TIA = transient ischemic attack.
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fiable risk factor for the development of delirium.19
In terms of implications for future research, given the
pooled prevalence of delirium following TAVI is 23%, fur-
ther studies examining the prevalence of delirium following
TAVI procedure should have a sample size of at least 385
participants to be adequately powered (see Supplement
Table 1 for calculations). Primary studies should ensure
delirium is assessed daily for a minimum of 2 days follow-
ing TAVI as this is the most common time to develop delir-
ium.16,17 Future research on risk factors for delirium
following TAVI procedure should include modifiable risk
factors that have been identified in other hospital popula-
tions including dehydration, electrolyte abnormalities, liver
failure, urinary tract infection, pneumonia, physical
restraints, bladder catheters, polypharmacy, hearing and
vision.19 In addition, the effectiveness of delirium preventa-
tive measures in elderly hospitalized adults6 could be evalu-
ated in the TAVI population.Disclosures
The authors have no relevant disclosures.
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